Omalizumab in the treatment of chronic spontaneous urticaria was not associated with any negative maternal or fetal outcomes when administered before and after pregnancy, in a recent retrospective study. Omalizumab is a monoclonal antibody against immunoglobulin E (IgE) that is recommended for individuals with medication-resistant moderate-to-severe persistent asthma, chronic spontaneous urticaria (CSU), and nasal polyps...